Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Caries experience (mean DMFT) · Adults aged 19-60 years
Pooled caries experience (DMFT) was similar in very-high-HDI and high-HDI countries, and meta-regression found no significant association between national HDI and DMFT; ungraded observational evidence with very high heterogeneity.
3 findings from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
Height velocity (cm/year) · children and young adults with CF
1 finding from 1 review
Change in weight (kg) · children and young adults with CF
1 finding from 1 review
QoL · children and young adults with CF
1 finding from 1 review
Fasting blood glucose (mg/dL) · children and young adults with CF
1 finding from 1 review
Number of pulmonary exacerbations or hospitalisations · children and young adults with CF
High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
Height velocity (cm/year) · children and young adults with CF
1 finding from 1 review
Change in weight (kg) · children and young adults with CF
1 finding from 1 review
QoL · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fasting blood glucose (mg/dL) · children and young adults with CF
1 finding from 1 review
Number of pulmonary exacerbations or hospitalisations · children and young adults with CF
High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).
1 finding from 1 review